ロード中...
Long-term safety and immunogenicity of the M72/AS01(E) candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial
OBJECTIVES: To assess the long-term safety and immunogenicity of the M72/ Adjuvant System (AS01(E)) candidate tuberculosis (TB) vaccine up to 3 years post-dose 2 (Y3) in human immunodeficiency virus (HIV)-positive (HIV+) and HIV-negative (HIV−) Indian adults. METHODS: This phase II, double-blind, ra...
保存先:
| 出版年: | Medicine (Baltimore) |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6250513/ https://ncbi.nlm.nih.gov/pubmed/30407329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013120 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|